



Practical Challenges in Real World Evidence (RWE) Studies

Andisheh Bakhshi

(Senior Biostatistician; MSc, FHEA, PhD)

With Heart™



Sheffield, UK, Europe



andisheh.bakhshi@parexel.com




Disclaimer

The contents of this presentation are my own, and do not necessarily reflect the views and/or policies of Parexel.



Real-World Data (RWD)

“The data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources”¹




¹ International Harmonisation of Real-World Evidence Terminology and Convergence of 4 General Principles Regarding Planning and Reporting of Studies Using Real-World Data, with 5 a Focus on Effectiveness of Medicines, 2023, quoted from FDA

Real-World Evidence (RWE)

- *“Clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD”¹*
- Turn the raw data into useful source for stakeholder
- Transform diverse types of evidence into information on health care
- Use RWD to utilise authorized medicines in routine medical practice
- Generate evidence that supports regulatory decisions on post-marketing safety and effectiveness of medicines



¹ International Harmonisation of Real-World Evidence Terminology and Convergence of 4 General Principles Regarding Planning and Reporting of Studies Using Real-World Data, with 5 a Focus on Effectiveness of Medicines, 2023, quoted from FDA



Challenges



The handling of data collection and analysis in real-world Evidence studies present significant challenges, mainly due to fewer regulations in place compared to clinical trial studies.

Many of which can potentially cause inaccuracy and biasness in final analysis.

Here only a handful of challenges that I became aware of in the two recent non-interventional studies I am working on.

RWE Study Challenges

Study Design

Inconsistent Regulations

Data Management

Programming & Analysis

- Scientific question may be lacking ==> check proxies to start with
- Scientific question is known but not collected
 - No guarantee what can be achieved
 - Quality of data not promising
- Retrospective:
 - No control of data availability
 - No easy to track missing data back
- Prospective: Can decide what to collect ==> expensive

RWE Study Challenges

Study Design

Inconsistent Regulations

Data Management

Programming & Analysis

RWE
Retrospective



Consent Form
required in
some countries



Oncology:
Person may not
be alive anymore



Missing
possibly
important data



Not easy to ask
families
(emotional
reasons)

RWE Study Challenges

Study Design

Inconsistent Regulations

Data Management

Programming & Analysis

- In some countries ICF is not required if data is fully anonymised
 - Limits the type of access, site training and data record
 - Might end up changing endpoint
 - Can damage the research

RWE Study Challenges

Study Design

Inconsistent Regulations

Data Management

Programming & Analysis

- Non-standard approach to CRF design
 - Present database to accommodate the RWD setting
- Different standard of care
 - Data lost by patient
 - Data not documented
 - Patient moved to another area
 - Case by case need to be accommodated
- Staff availability and data varying scheduled visits
 - ==> Delay in entry and timelines



RWE Study Challenges

Study Design

Inconsistent Regulations

Data Management

Programming & Analysis

Dataset Programming

Unplanned data

Not fitted into any source forms

Nature of data to be determined

Multiple discussions with DM

Occasionally to be assigned to multiple source for consistency

It's RWD! No success! Cannot be fixed

RWE Study Challenges

Study Design

Inconsistent Regulations

Data Management

Programming & Analysis

Mapping

Data in non-standard field

Request to use standard field

Standard group may not approve

Study team approval

Non-standard programming methods

RWE Study Challenges

Study Design

Inconsistent Regulations

Data Management

Programming & Analysis

Ineligible subjects



Not removed by DM
==> data issue



Manual programming



Programme at dataset level



Output programmes to be updated



Documentation required

RWE Study Challenges

Study Design

Inconsistent Regulations

Data Management

Programming & Analysis

Output submission



Non-standard programming



Pinnacle 21 generates issues



Documents needed for clarifications

Remarks



- Fewer regulations in place for RWD can challenge RWE studies in all stages from study design all the way to providing analysis to stakeholders.
- RWE are financially feasible though to complement clinical trials and study more outcomes in bigger patients' population

Acknowledgement



Helen Brown (Statistics Manager) for her support and facilitating this trip



Venkanna Chittimalla (Principal Statistical Programmer),
Co-author



Nadia McMaster (Senior Data Management
Lead), Co-author



Thank you

parexel[®]

© 2024 Parexel International (MA) Corporation / CONFIDENTIAL